DK1188768T3 - LHRH-antagonisk-peptider - Google Patents

LHRH-antagonisk-peptider

Info

Publication number: DK1188768T3
Authority: DK; Denmark
Prior art keywords: moiety; lhrh antagonist; antagonist peptides; lhrh; peptide compound
Prior art date: 1995-06-07

Application number

DK01204149T

Other languages

English (en)

Inventor

Roger W Roeske

Original Assignee

Univ Indiana Res & Tech Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1996-06-07

Publication date

2009-09-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23908180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1188768(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-06-07 Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp

2009-09-21 Application granted granted Critical

2009-09-21 Publication of DK1188768T3 publication Critical patent/DK1188768T3/da

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title abstract 3
239000002474 gonadorelin antagonist Substances 0.000 title abstract 3
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 abstract 1
102100024028 Progonadoliberin-1 Human genes 0.000 abstract 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 abstract 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 1
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium group Chemical group [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/13—Luteinizing hormone-releasing hormone; related peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Reproductive Health (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK01204149T 1995-06-07 1996-06-07 LHRH-antagonisk-peptider DK1188768T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/480,494 US5843901A (en)	1995-06-07	1995-06-07	LHRH antagonist peptides
PCT/US1996/009852 WO1996040757A2 (en)	1995-06-07	1996-06-07	Lhrh antagonist peptides

Publications (1)

Publication Number	Publication Date
DK1188768T3 true DK1188768T3 (da)	2009-09-21

Family

ID=23908180

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK01204149T DK1188768T3 (da)	1995-06-07	1996-06-07	LHRH-antagonisk-peptider
DK96919311T DK0794961T3 (da)	1995-06-07	1996-06-07	LHRH-antagonistpeptider

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK96919311T DK0794961T3 (da)	1995-06-07	1996-06-07	LHRH-antagonistpeptider

Country Status (13)

Country	Link
US (4)	US5843901A (da)
EP (2)	EP1188768B1 (da)
JP (3)	JP4164125B2 (da)
AT (2)	ATE222924T1 (da)
AU (1)	AU715399B2 (da)
CA (1)	CA2219460C (da)
DE (4)	DE122006000012I2 (da)
DK (2)	DK1188768T3 (da)
ES (2)	ES2326861T3 (da)
HK (1)	HK1045161B (da)
LU (2)	LU91225I2 (da)
PT (2)	PT794961E (da)
WO (1)	WO1996040757A2 (da)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL117175A (en) *	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
US5843901A (en) *	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
US5780435A (en) *	1995-12-15	1998-07-14	Praecis Pharmaceuticals Incorporated	Methods for treating prostate cancer with LHRH-R antagonists
US5968895A (en)	1996-12-11	1999-10-19	Praecis Pharmaceuticals, Inc.	Pharmaceutical formulations for sustained drug delivery
ATE497001T1 (de) *	1996-12-23	2011-02-15	Immunex Corp	Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US5925730A (en) *	1997-04-11	1999-07-20	Ferring Bv	GnRH antagonists
JP3523650B2 (ja) *	1997-04-15	2004-04-26	三共株式会社	新規蛋白質及びその製造方法
EA003636B1 (ru)	1997-04-16	2003-08-28	Амген Инк.	Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) *	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
US6217844B1 (en) *	1998-04-27	2001-04-17	Praecis Pharmaceuticals, Inc.	Methods for detecting lesions in dense breast tissue using LHRH antagonists
CN1307481A (zh) *	1998-04-27	2001-08-08	普雷西斯药品公司	用于治疗热潮红和男子女性型乳房的方法
US6191115B1 (en) *	1998-08-12	2001-02-20	Abbott Laboratories	C-terminus modified heptapeptide LHRH analogs
US6455499B1 (en) *	1999-02-23	2002-09-24	Indiana University Foundation	Methods for treating disorders associated with LHRH activity
US6703367B1 (en) *	1999-04-27	2004-03-09	Praecis Pharmaceuticals Inc.	Methods for treating hot flashes and gynaecomastia
CN1377276A (zh) *	1999-08-09	2002-10-30	特里帕普股份公司	含有三肽的药用组合物
KR20010085996A (ko) *	1999-09-03	2001-09-07	스티븐 엠. 오드레	암 및 암관련 골손실을 예방 또는 치료하는 조성물 및 방법
US20030103978A1 (en)	2000-02-23	2003-06-05	Amgen Inc.	Selective binding agents of osteoprotegerin binding protein
US7109171B2 (en) *	2000-02-28	2006-09-19	Praecis Pharmaceuticals Inc.	Methods for treating FSH related conditions with GnRH antagonists
KR20030021184A (ko) *	2000-06-30	2003-03-12	산또리 가부시키가이샤	신규 생식선 자극 호르몬 방출 호르몬, 이의 전구체폴리펩티드 및 이들을 코딩하는 유전자
US6598784B2 (en) *	2000-12-20	2003-07-29	Meadwestvaco Packaging Syatens, Llc	Beverage carton with strap type carrying handle
WO2002056903A2 (en) *	2001-01-17	2002-07-25	Praecis Pharmaceuticals Inc.	Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
CN1551767A (zh)	2001-02-19	2004-12-01	��˹��ŵ��	癌症的治疗
AU2002342335B2 (en)	2001-05-16	2006-02-02	Novartis Ag	Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
CA2451187C (en)	2001-06-22	2012-08-14	Southern Biosystems, Inc.	Zero-order prolonged release coaxial implants
TR201809678T4 (tr)	2001-06-26	2018-07-23	Amgen Fremont Inc	Opgl ye karşi antikorlar.
US6593455B2 (en) *	2001-08-24	2003-07-15	Tripep Ab	Tripeptide amides that block viral infectivity and methods of use thereof
GB0128510D0 (en) *	2001-11-28	2002-01-23	Novartis Ag	Organic compounds
AU2003243139B2 (en)	2002-04-05	2007-06-21	Amgen Inc.	Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
JP5227492B2 (ja)	2002-05-16	2013-07-03	ノバルティスアーゲー	癌におけるｅｄｇレセプター結合剤の使用
US6861236B2 (en)	2002-05-24	2005-03-01	Applied Nanosystems B.V.	Export and modification of (poly)peptides in the lantibiotic way
US8709998B2 (en)	2003-04-22	2014-04-29	Ipsen Pharma S.A.S.	Peptide vectors
GB0320806D0 (en)	2003-09-05	2003-10-08	Astrazeneca Ab	Therapeutic treatment
JP4407322B2 (ja) *	2004-03-09	2010-02-03	味の素株式会社	ペプチドの製造方法
PL2253614T3 (pl)	2004-04-07	2013-03-29	Novartis Ag	Inhibitory IAP
GB0512324D0 (en)	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
EP1845973B1 (en)	2005-01-21	2015-08-12	Astex Therapeutics Limited	Pharmaceutical compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
EP1996550A2 (en)	2005-09-27	2008-12-03	Novartis AG	Carboxyamine compounds and their use in the treatment of hdac dependent diseases
US20070106271A1 (en) *	2005-11-09	2007-05-10	Searete Llc, A Limited Liability Corporation	Remote control of substance delivery system
GB0605120D0 (en)	2006-03-14	2006-04-26	Novartis Ag	Organic Compounds
JP2009536180A (ja)	2006-05-09	2009-10-08	ノバルティスアクチエンゲゼルシャフト	鉄キレート剤と抗新生物剤を含む組合せ剤およびそれらの使用
JP2010504933A (ja)	2006-09-29	2010-02-18	ノバルティスアーゲー	Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
US8916552B2 (en)	2006-10-12	2014-12-23	Astex Therapeutics Limited	Pharmaceutical combinations
US8883790B2 (en)	2006-10-12	2014-11-11	Astex Therapeutics Limited	Pharmaceutical combinations
CA2677651A1 (en)	2007-02-15	2008-08-21	Novartis Ag	Combinations of therapeutic agents for treating cancer
ES2524259T3 (es)	2008-03-24	2014-12-04	Novartis Ag	Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida
EA019033B1 (ru)	2008-03-26	2013-12-30	Новартис Аг	Ингибиторы дезацетилазы в, основанные на гидроксамате
BRPI0922301A2 (pt) *	2008-11-28	2019-02-26	Novartis Ag	combinações de inibidor de hsp90
WO2010083617A1 (en)	2009-01-21	2010-07-29	Oncalis Ag	Pyrazolopyrimidines as protein kinase inhibitors
CA2750582A1 (en)	2009-01-22	2010-07-29	Maatschap Interne Geneeskunde Rijnstate	Method for the prophylaxis or treatment of flushing
ES2396023T3 (es)	2009-01-29	2013-02-18	Novartis Ag	Bencimidazoles sustituidos para el tratamiento de astrocitomas
PE20121048A1 (es)	2009-06-26	2012-08-25	Novartis Ag	Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt)	2009-08-12	2016-05-17	Novartis Ag	compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
IN2012DN01453A (da)	2009-08-20	2015-06-05	Novartis Ag
EA201200321A1 (ru)	2009-08-26	2012-09-28	Новартис Аг	Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
CA2773661A1 (en)	2009-09-10	2011-03-17	Novartis Ag	Ether derivatives of bicyclic heteroaryls
BR112012010519A2 (pt)	2009-11-04	2017-12-05	Novartis Ag	derivados de sulfonamida heterocíclicos
WO2011064211A1 (en)	2009-11-25	2011-06-03	Novartis Ag	Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
PE20121384A1 (es)	2009-12-08	2012-10-13	Novartis Ag	Derivados de sulfonamida heterociclicos
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
UA112517C2 (uk)	2010-07-06	2016-09-26	Новартіс Аг	Тетрагідропіридопіримідинові похідні
SG177783A1 (en)	2010-07-09	2012-02-28	Smart Communications Inc	Content provision system and method
EP2627648A1 (en)	2010-09-16	2013-08-21	Novartis AG	17aHYDROXYLASE/C17,20-LYASE INHIBITORS
SI2640467T1 (sl)	2010-11-19	2015-04-30	Novartis Ag	Kristalinična oblika inhibitorja interakcije MDM2/4 in P53
WO2012107500A1 (en)	2011-02-10	2012-08-16	Novartis Ag	[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
CN103492390A (zh)	2011-03-08	2014-01-01	诺瓦提斯公司	氟苯基双环杂芳基化合物
MX359399B (es)	2011-04-28	2018-09-27	Novartis Ag	Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
IN2014DN00123A (da)	2011-06-09	2015-05-22	Novartis Ag
EP2721007B1 (en)	2011-06-20	2015-04-29	Novartis AG	Cyclohexyl isoquinolinone compounds
EP2721008B1 (en)	2011-06-20	2015-04-29	Novartis AG	Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors
EP2723740A1 (en)	2011-06-27	2014-04-30	Novartis AG	Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
UY34329A (es)	2011-09-15	2013-04-30	Novartis Ag	Compuestos de triazolopiridina
WO2013080141A1 (en)	2011-11-29	2013-06-06	Novartis Ag	Pyrazolopyrrolidine compounds
EP2794594A1 (en)	2011-12-22	2014-10-29	Novartis AG	Quinoline derivatives
IN2014CN04174A (da)	2011-12-22	2015-09-04	Novartis Ag
AU2012355623A1 (en)	2011-12-23	2014-07-17	Novartis Ag	Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355613A1 (en)	2011-12-23	2014-07-17	Novartis Ag	Compounds for inhibiting the interaction of BCL2 with binding partners
AU2012355624A1 (en)	2011-12-23	2014-07-17	Novartis Ag	Compounds for inhibiting the interaction of BCL2 with binding partners
CA2859873A1 (en)	2011-12-23	2013-06-27	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
EA201491265A1 (ru)	2011-12-23	2014-11-28	Новартис Аг	Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
UY34591A (es)	2012-01-26	2013-09-02	Novartis Ag	Compuestos de imidazopirrolidinona
WO2013148727A1 (en) *	2012-03-26	2013-10-03	The Regents Of The University Of California	Preparation of functionalized polypeptides, peptides, and proteins by alkylation of thioether groups
EP2855483B1 (en)	2012-05-24	2017-10-25	Novartis AG	Pyrrolopyrrolidinone compounds
JP6427097B2 (ja)	2012-06-15	2018-11-21	ザブリガムアンドウィメンズホスピタルインコーポレイテッドＴｈｅＢｒｉｇｈａｍａｎｄＷｏｍｅｎ’ｓＨｏｓｐｉｔａｌ，Ｉｎｃ．	癌を処置するための組成物および該組成物を製造するための方法
ES2654143T3 (es)	2012-10-02	2018-02-12	Gilead Sciences, Inc.	Inhibidores de desmetilasas de histonas
TW201422625A (zh)	2012-11-26	2014-06-16	Novartis Ag	二氫－吡啶并－□衍生物之固體形式
WO2014115080A1 (en)	2013-01-22	2014-07-31	Novartis Ag	Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
US9403827B2 (en)	2013-01-22	2016-08-02	Novartis Ag	Substituted purinone compounds
WO2014128612A1 (en)	2013-02-20	2014-08-28	Novartis Ag	Quinazolin-4-one derivatives
SG10201707027SA (en)	2013-02-27	2017-09-28	Epitherapeutics Aps	Inhibitors of histone demethylases
US20150018376A1 (en)	2013-05-17	2015-01-15	Novartis Ag	Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
UY35675A (es)	2013-07-24	2015-02-27	Novartis Ag	Derivados sustituidos de quinazolin-4-ona
US9227969B2 (en)	2013-08-14	2016-01-05	Novartis Ag	Compounds and compositions as inhibitors of MEK
WO2015022663A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
WO2015022664A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
KR20160060100A (ko)	2013-09-22	2016-05-27	칼리토르 사이언시즈, 엘엘씨	치환된 아미노피리미딘 화합물 및 이용 방법
MX2016009226A (es)	2014-01-15	2016-10-05	Novartis Ag	Combinaciones farmaceuticas.
US9399637B2 (en)	2014-03-28	2016-07-26	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
JP2017512804A (ja)	2014-03-31	2017-05-25	ギリアードサイエンシーズ，インコーポレイテッド	ヒストン脱メチル化酵素の阻害剤
WO2015153345A1 (en)	2014-04-03	2015-10-08	Invictus Oncology Pvt. Ltd.	Supramolecular combinatorial therapeutics
JP2017526675A (ja)	2014-08-27	2017-09-14	ギリアードサイエンシーズ，インコーポレイテッド	ヒストンデメチラーゼを阻害するための化合物および方法
US10351591B2 (en)	2015-03-20	2019-07-16	The Regents Of The University Of California	Polypeptides, peptides, and proteins functionalized by alkylation of thioether groups via ring-opening reactions
EP3124495A1 (en)	2015-07-31	2017-02-01	Centre National de la Recherche Scientifique (C.N.R.S.)	Derivatives of elastin-like polypeptides and uses thereof
EP3347097B1 (en)	2015-09-11	2021-02-24	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
WO2017189860A1 (en)	2016-04-27	2017-11-02	The Regents Of The University Of California	Preparation of functional homocysteine residues in polypeptides and peptides
WO2019099311A1 (en)	2017-11-19	2019-05-23	Sunshine Lake Pharma Co., Ltd.	Substituted heteroaryl compounds and methods of use
EP3730483B1 (en)	2017-12-21	2023-08-30	Hefei Institutes of Physical Science, Chinese Academy of Sciences	Class of pyrimidine derivative kinase inhibitors
EP3740468B1 (en)	2018-01-20	2025-12-31	Sunshine Lake Pharma Co., Ltd.	Substituted Aminopyrimidine Compounds and Methods of Use
CN109926430A (zh) *	2018-11-19	2019-06-25	云南省环境科学研究院(中国昆明高原湖泊国际研究中心)	一种重金属废渣还原造锍熔炼处置的方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3787385A (en) *	1971-05-17	1974-01-22	K Folkers	Synthetically produced tetrapeptide having the activity of the luteinizing hormone releasing hormone
US3974135A (en) *	1971-06-24	1976-08-10	Karl Folkers	Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for producing the same
US3953416A (en) *	1971-12-20	1976-04-27	Karl Folkers	Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for manufacturing the same
DE2649146A1 (de) *	1975-10-29	1977-05-12	Parke Davis & Co	Nonapeptide
DE2649114A1 (de) *	1975-10-29	1977-05-12	Parke Davis & Co	Octapeptide
DE2617646C2 (de) *	1976-04-22	1986-07-31	Hoechst Ag, 6230 Frankfurt	Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
US4215038A (en) *	1978-10-16	1980-07-29	The Salk Institute For Biological Studies	Peptides which inhibit gonadal function
US4307083A (en) *	1978-10-16	1981-12-22	The Salk Institute For Biological Studies	LRF Antagonists
US4244946A (en) *	1979-06-11	1981-01-13	The Salk Institute For Biological Studies	Water-soluble peptides affecting gonadal function
US4292313A (en) *	1980-04-15	1981-09-29	The Salk Institute For Biological Studies	LRF Antagonists
US4409208A (en) *	1980-04-15	1983-10-11	The Salk Institute For Biological Studies	GnRH antagonists
US4377574A (en) *	1980-06-26	1983-03-22	The Salk Institute For Biological Studies	Contraceptive treatment of male mammals
US4386074A (en) *	1980-08-29	1983-05-31	The Salk Institute For Biological Studies	LRF Antagonists
US4341767A (en) *	1980-10-06	1982-07-27	Syntex Inc.	Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4419347A (en) *	1980-10-06	1983-12-06	Syntex (U.S.A.) Inc.	Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4489061A (en) *	1981-06-12	1984-12-18	The Salk Institute For Biological Studies	Treatment of male mammals
US4481190A (en) *	1982-12-21	1984-11-06	Syntex (U.S.A.) Inc.	Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4581169A (en) *	1982-12-21	1986-04-08	Syntex (U.S.A.) Inc.	Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists
US4667014A (en) *	1983-03-07	1987-05-19	Syntex (U.S.A.) Inc.	Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4444759A (en) *	1982-07-26	1984-04-24	The Salk Institute For Biological Studies	GnRH Antagonists II
US4619914A (en) *	1983-03-10	1986-10-28	The Salk Institute For Biological Studies	GNRH antagonists IIIB
US4504414A (en) *	1983-03-28	1985-03-12	Board Of Regents, The University Of Texas System	Synthetic pyridyl-alanyl decapeptides having antiovulatory activity
DE3467173D1 (en) *	1983-08-16	1987-12-10	Akzo Nv	Lh- rh antagonists
US4547370A (en) *	1983-11-29	1985-10-15	The Salk Institute For Biological Studies	GnRH Antagonists
US4569927A (en) *	1984-02-23	1986-02-11	The Salk Institute For Biological Studies	GnRH Antagonists IV
US4652550A (en) *	1984-05-21	1987-03-24	The Salk Institute For Biological Studies	GnRH antagonists VII
US4647653A (en) *	1984-08-23	1987-03-03	Tulane Educational Fund	Therapeutic peptides
US4565804A (en) *	1984-09-07	1986-01-21	The Salk Institute For Biological Studies	GnRH Antagonists VI
US4690916A (en) *	1984-11-13	1987-09-01	Syntex (U.S.A.) Inc.	Nona and decapeptide analogs of LHRH useful as LHRH antagonists
US4740500A (en) *	1985-01-31	1988-04-26	The Salk Institute For Biological Studies	GnRH antagonists VIII
US4659691A (en) *	1985-02-08	1987-04-21	Merck & Co., Inc.	Novel cyclic Hexapeptide LHRH antagonists
US4677193A (en) *	1985-02-22	1987-06-30	The Salk Institute For Biological Studies	Peptides containing an aliphatic-aromatic ketone side chain
US4866160A (en) *	1985-04-09	1989-09-12	The Administrators Of The Tulane Educational Fund	Therapeutic decapeptides
US5073624A (en) *	1985-04-09	1991-12-17	Administrators Of The Tulane Educational Fund	Therapeutic decapeptides
US5003011A (en) *	1985-04-09	1991-03-26	The Administrators Of The Tulane Educational Fund	Therapeutic decapeptides
US4656247A (en) *	1985-04-26	1987-04-07	Board Of Regents, The University Of Texas System	Effective hormonal peptides: D-3-QA1 6-LHRH
US4642332A (en) *	1985-04-26	1987-02-10	The Board Of Regents, The University Of Texas System	Effective hormonal peptides: D-3-Pal6 -LHRH
US4661472A (en) *	1985-05-09	1987-04-28	The Salk Institute For Biological Studies	GnRH antagonists IX
US4721775A (en) *	1985-08-26	1988-01-26	Board Of Regents, The University Of Texas System	Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
US4705778A (en) *	1985-10-22	1987-11-10	Sri International	Orally active LHRH analogs
US5182205A (en) *	1986-11-27	1993-01-26	Hoffmann-La Roche Inc.	Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
US4801577A (en) *	1987-02-05	1989-01-31	Syntex (U.S.A.) Inc.	Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4851385A (en) *	1987-07-15	1989-07-25	Indiana University Foundation	LHRH antagonist analogs having low histamine-release activity
US4800191A (en) *	1987-07-17	1989-01-24	Schally Andrew Victor	LHRH antagonists
US4935491A (en) *	1987-08-24	1990-06-19	Board Of Regents, The University Of Texas System	Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5140009A (en) *	1988-02-10	1992-08-18	Tap Pharmaceuticals, Inc.	Octapeptide LHRH antagonists
US5110904A (en) *	1989-08-07	1992-05-05	Abbott Laboratories	Lhrh analogs
DE68928278T2 (de) *	1988-02-10	1998-03-12	Tap Pharmaceuticals Inc	Lhrh-analog
US5300492A (en) *	1988-02-10	1994-04-05	Tap Pharmaceuticals	LHRH analogs
DK163689A (da) *	1988-04-08	1989-10-30	Sandoz Ag	Peptidderivater
US4992421A (en) *	1988-04-19	1991-02-12	Abbott Laboratories	Luteinizing hormone releasing hormone antagonist
US5171835A (en) *	1988-10-21	1992-12-15	The Administrators Of The Tulane Educational Fund	LHRH antagonists
US5258492A (en) *	1988-10-21	1993-11-02	The Administrators Of The Tulane Educational Fund	LHRH analogues with cytotoxic moieties at the sixth position
US5296468A (en) *	1989-10-30	1994-03-22	The Salk Institute For Biological Studies	GnRH analogs
US5352796A (en) *	1989-10-30	1994-10-04	The Salk Institute For Biological Studies	Amino acids useful in making GnRH analogs
US5169932A (en) *	1989-10-30	1992-12-08	The Salk Institute For Biological Studies	Gnrh analogs
US5064939A (en) *	1990-02-06	1991-11-12	The Salk Institute For Biological Studies	Cyclic gnrh antagonists
US5180711A (en) *	1990-06-14	1993-01-19	Applied Research Systems Ars Holding N.V.	Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals
CN1036343C (zh) *	1990-11-10	1997-11-05	天津市计划生育研究所	新促黄体生成素释放激素拮抗类似物的制备方法
IL101074A (en) *	1991-03-14	1997-09-30	Salk Inst For Biological Studi	GnRH ANALOGS AND THEIR PREPARATION
US5340585A (en) *	1991-04-12	1994-08-23	University Of Southern California	Method and formulations for use in treating benign gynecological disorders
ATE144538T1 (de) *	1991-04-25	1996-11-15	Romano Deghenghi	Lhrh-antagonisten
DE4117507A1 (de) *	1991-05-24	1992-11-26	Schering Ag	Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten
US5480969A (en) *	1992-09-15	1996-01-02	The Administrators Of The Tulane Educational Fund	Antagonists of LHRH
US5371070A (en) *	1992-11-09	1994-12-06	The Salk Institute For Biological Studies	Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins
CA2136078A1 (en) *	1992-12-04	1994-06-23	Jonathan Greer	6-position modified decapeptide lhrh antagonists
CA2136079A1 (en) *	1992-12-18	1994-07-07	Fortuna Haviv	Lhrh antagonists having modified aminoacyl residues at positions 5 and 6
CA2163225A1 (en) *	1993-05-20	1994-12-08	Gregory John Russell-Jones	Lhrh antagonists
DE4320201A1 (de) *	1993-06-18	1995-01-12	Asta Medica Ag	Verwendung von Cetrorelix und weiteren Nona- und Dekapeptiden zur Herstellung eines Arzneimittels zur Bekämpfung von Aids und zur Wachstumsstimulation
US5502035A (en) *	1993-08-06	1996-03-26	Tap Holdings Inc.	N-terminus modified analogs of LHRH
US5413990A (en) *	1993-08-06	1995-05-09	Tap Pharmaceuticals Inc.	N-terminus modified analogs of LHRH
US5508383A (en) *	1994-03-09	1996-04-16	Tap Holdings Inc.	Cyclic peptide LHRH antagonists
US5506207A (en) *	1994-03-18	1996-04-09	The Salk Institute For Biological Studies	GNRH antagonists XIII
US5516759A (en) *	1994-12-08	1996-05-14	Tap Holdings Inc.	LHRH antagonists having lactam groups at the N-terminus
US5843901A (en) *	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
US5780435A (en) *	1995-12-15	1998-07-14	Praecis Pharmaceuticals Incorporated	Methods for treating prostate cancer with LHRH-R antagonists

1995
- 1995-06-07 US US08/480,494 patent/US5843901A/en not_active Expired - Lifetime
1996
- 1996-06-07 DE DE122006000012C patent/DE122006000012I2/de active Active
- 1996-06-07 PT PT96919311T patent/PT794961E/pt unknown
- 1996-06-07 ES ES01204149T patent/ES2326861T3/es not_active Expired - Lifetime
- 1996-06-07 CA CA002219460A patent/CA2219460C/en not_active Expired - Fee Related
- 1996-06-07 AT AT96919311T patent/ATE222924T1/de active
- 1996-06-07 DE DE1996623254 patent/DE122006000012I1/de active Pending
- 1996-06-07 JP JP50205097A patent/JP4164125B2/ja not_active Expired - Fee Related
- 1996-06-07 US US08/973,378 patent/US6423686B1/en not_active Expired - Lifetime
- 1996-06-07 DE DE69623254T patent/DE69623254T2/de not_active Expired - Lifetime
- 1996-06-07 AU AU61680/96A patent/AU715399B2/en not_active Ceased
- 1996-06-07 AT AT01204149T patent/ATE432941T1/de active
- 1996-06-07 DE DE69535963T patent/DE69535963D1/de not_active Expired - Lifetime
- 1996-06-07 WO PCT/US1996/009852 patent/WO1996040757A2/en not_active Ceased
- 1996-06-07 DK DK01204149T patent/DK1188768T3/da active
- 1996-06-07 DK DK96919311T patent/DK0794961T3/da active
- 1996-06-07 EP EP01204149A patent/EP1188768B1/en not_active Expired - Lifetime
- 1996-06-07 EP EP96919311A patent/EP0794961B1/en not_active Expired - Lifetime
- 1996-06-07 PT PT01204149T patent/PT1188768E/pt unknown
- 1996-06-07 ES ES96919311T patent/ES2177789T3/es not_active Expired - Lifetime
2002
- 2002-04-02 US US10/115,553 patent/US20030040482A1/en not_active Abandoned
- 2002-04-05 US US10/117,364 patent/US7071165B2/en not_active Expired - Fee Related
- 2002-09-11 HK HK02106667.7A patent/HK1045161B/en not_active IP Right Cessation
2006
- 2006-03-03 LU LU91225C patent/LU91225I2/fr unknown
2007
- 2007-08-13 JP JP2007211155A patent/JP2007302695A/ja not_active Withdrawn
2008
- 2008-10-09 JP JP2008263288A patent/JP2009040793A/ja not_active Withdrawn
2011
- 2011-08-22 LU LU91857C patent/LU91857I2/fr unknown

Also Published As

Publication number	Publication date
LU91857I2 (fr)	2011-10-24
EP0794961B1 (en)	2002-08-28
ATE222924T1 (de)	2002-09-15
DE122006000012I2 (de)	2010-02-04
WO1996040757A3 (en)	1997-02-20
EP1188768A3 (en)	2002-10-23
CA2219460C (en)	2009-04-14
US7071165B2 (en)	2006-07-04
ES2326861T3 (es)	2009-10-21
DE122006000012I1 (de)	2006-06-29
JP2007302695A (ja)	2007-11-22
US20020115615A1 (en)	2002-08-22
PT794961E (pt)	2003-01-31
AU6168096A (en)	1996-12-30
ATE432941T1 (de)	2009-06-15
DE69623254D1 (de)	2002-10-02
PT1188768E (pt)	2009-08-13
EP1188768A2 (en)	2002-03-20
LU91225I2 (fr)	2006-05-03
JP2009040793A (ja)	2009-02-26
DE69623254T2 (de)	2002-12-19
ES2177789T3 (es)	2002-12-16
AU715399B2 (en)	2000-02-03
JPH11507374A (ja)	1999-06-29
DE69535963D1 (de)	2009-07-16
HK1045161A1 (en)	2002-11-15
HK1045161B (en)	2009-12-24
US20030181385A1 (en)	2003-09-25
US20030040482A1 (en)	2003-02-27
CA2219460A1 (en)	1996-12-19
US5843901A (en)	1998-12-01
WO1996040757A2 (en)	1996-12-19
DK0794961T3 (da)	2002-10-21
EP0794961A2 (en)	1997-09-17
EP1188768B1 (en)	2009-06-03
JP4164125B2 (ja)	2008-10-08
US6423686B1 (en)	2002-07-23

Publication	Publication Date	Title
DK0794961T3 (da)	2002-10-21	LHRH-antagonistpeptider
PT1288223E (pt)	2005-03-31	Derivados de peptidos terapeuticos
LV10720A (lv)	1995-06-20	Peptidi un farmaceitiska kompozicija uz to bazes
DK0966297T4 (da)	2013-03-18	Regulering af gastrointestinal motilitet
ATE196296T1 (de)	2000-09-15	Dolastatin analog
ATE108662T1 (de)	1994-08-15	Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
FI102759B (fi)	1999-02-15	Menetelmä terapeuttisesti aktiivisten nona- ja dekapeptidien valmistam iseksi
BG97123A (bg)	1993-12-24	Производни на човешка, стимулирана от жлъчните соли, липаза и фармацевтични състави на тяхна основа
DK482185D0 (da)	1985-10-21	Peptider, deres fremstilling og anvendelse som laegemidler
DE60044945D1 (de)	2010-10-21	Auf scf peptid basiertes basolaterales sortiersignal und inhibitoren dafür
FI883643A0 (fi)	1988-08-04	Cyklopeptider som befraemjar absorption under anvaendning pao slemhinnorna.
NZ231636A (en)	1993-03-26	Anticoagulant peptides analogus to hirudins' active site
DE69002881D1 (de)	1993-09-30	Peptide und deren Benutzung.
DK1612555T3 (da)	2009-02-09	Kryptiske peptider til anvendelse til at inducere immunologisk tolerance
IT8720701A0 (it)	1987-05-28	Composizioni farmaceutiche adattivita' immunomodulante.
IT8520273A0 (it)	1985-04-05	Composizioni farmaceutiche adattivita' antigalattopoietica.
IT8719949A0 (it)	1987-04-02	Composizioni farmaceutiche adattivita' immunomodulante.
IT8847610A0 (it)	1988-02-05	Composizioni farmaceutiche adattivita' antiprolattinica
IT8622051A0 (it)	1986-10-17	Composizioni farmaceutiche adattivita' cicatrizzante.
FI991120A0 (fi)	1999-05-17	Vesiliukoisten peptidien pitkäaikaisesti vapautuvat koostumukset
IT8820026A0 (it)	1988-03-30	Composizioni farmaceutiche adattivita' antineoplastica.